Skip to main content

Table 3 Risk of biochemical recurrence (BCR) by the new five-tier grade groupings among men having definitive treatment

From: Oncological outcomes in an Australian cohort according to the new prostate cancer grading groupings

Treatment subgroups

No. Events/Total

Competing risk regression

Unadjusted

sHR (95%CI)

p-value

Adjusted

sHRa (95%CI)

p-value

Radical prostatectomy

292/1351

    

Clinical grade groups N = 1351

     

 Grade group I (3 + 3)

57/541

1.0

-

1.0

-

 Grade group II (3 + 4)

94/468

2.0 (1.5–2.9)

<0.001

2.0 (1.4–2.8)

<0.001

 Grade group III (4 + 3)

73/200

4.1 (2.9–5.9)

<0.001

3.8 (2.9–5.9)

<0.001

 Grade group IV (8)

47/108

5.5 (3.7–8.0)

<0.001

5.3 (3.5–8.0)

<0.001

 Grade group V (9–10)

21/34

9.5 (5.6–16.1)

<0.001

11.2 (6.5–19.2)

<0.001

P for trend

  

<0.001

 

<0.001

Curative radiotherapy N = 937

185/937

    

 Grade group I (3 + 3)

46/321

1.0

-

1.0

-

 Grade group II (3 + 4)

42/254

1.2 (0.8–19)

0.291

1.2 (0.7–1.8)

0.32

 Grade group III (4 + 3)

51/187

2.4 (1.8–3.6)

<0.001

2.5 (1.5–3.7)

<0.001

 Grade group IV (8)

23/97

2.0 (1.2–3.4)

0.006

2.0 (0.9–2.9)

0.02

 Grade group V (9–10)

23/78

2.4 (1.8–5.2)

<0.001

2.4 (1.4–4.1)

0.001

P for trend

  

<0.001

 

<0.001

  1. Cases were excluded if <2 post- treatment PSA measures were recorded (273 (17%) cases excluded for prostatectomy group; 206 (18%) cases excluded for radiotherapy subgroup)
  2. asHR: Sub-distribution hazard ratios derived from competing risk regression adjusted for age, year of diagnosis, diagnostic PSA, clinical stage, area level SES, and public/private management
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us